Who are Placebo-matching Rapastinel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): acamprosate (Campral), NRX-101 Oral Capsule, Nerinetide (NA-1).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matching-rapastinel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo-matching Rapastinel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo-matching Rapastinel (Placebo-matching Rapastinel) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor modulator. Area: Psychiatry/Neurology.

phase 3 NMDA receptor modulator NMDA receptor (N-methyl-D-aspartate receptor) Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo-matching Rapastinel (Placebo-matching Rapastinel) — Naurex, Inc, an affiliate of Allergan plc. Rapastinel is an NMDA receptor modulator that enhances glutamatergic neurotransmission by potentiating NMDA receptor function to improve cognitive and psychiatric symptoms.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo-matching Rapastinel TARGET	Placebo-matching Rapastinel	Naurex, Inc, an affiliate of Allergan plc	phase 3	NMDA receptor modulator	NMDA receptor (N-methyl-D-aspartate receptor)
acamprosate (Campral)	acamprosate (Campral)	University of North Carolina, Chapel Hill	marketed	NMDA receptor modulator	NMDA receptor (glutamate); GABA system
NRX-101 Oral Capsule	NRX-101 Oral Capsule	NeuroRx, Inc.	phase 3	Fixed-dose combination (NMDA receptor modulator + atypical antipsychotic)	NMDA receptor (d-cycloserine component); dopamine D2 receptor and serotonin 5-HT7 receptor (lurasidone component)
Nerinetide (NA-1)	Nerinetide (NA-1)	NoNO Inc.	phase 3	NMDA receptor modulator / Neuroprotective peptide	PSD-95 (postsynaptic density protein 95)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor modulator class)

Naurex, Inc, an affiliate of Allergan plc · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo-matching Rapastinel — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matching-rapastinel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab